In Vivo Quantitative Mapping of Mitochondrial Cardiac Membrane Potential in Heart Failure

Laborértékek

• for all participants :
  • Infiltrative CMP (e.g., cardiac amyloidosis)
  • Hypertrophic CMP
  • Dilated CMP
  • Ischemic CMP with myocardial infarction
  • Other chronic diseases or medications that may interfere with mitochondrial function
  • Primary severe valvular disease
  • Pericardial disease
  • Pacemaker
  • Defibrillator
  • Congenital heart disease
  • History of cardiac transplant
  • BMI >45 kg/m2
  • High resting blood pressure ≥150/90 mmHg
  • Estimated glomerular filtration rate (eGFR) <50 mL/min/1.73m2
  • Iodinated contrast allergy
  • Women of child bearing potential
  • Pregnancy
  • Breastfeeding
  • Inability to undergo the imaging logistics
  • Any condition that, in the opinion of the investigator, could compromise the participation in the study

• Active participants:
  • ≥40 years old
  • LVEF ≥50%
  • Body Mass Index <35kg/m2
  • NYHA fuctional class I
  • Engaged in aerobic exercise (running cycling or swimming) for ≥3 days per week or 5 hours per week without extensive layoff over the previous 6 months
  • Non-smoker ≥1 year
  • Fasting glycemia <6.0 mmol/L
  • HbA1c <5.7%
• Sedentary participants:
  • ≥40 years old
  • LVEF ≥50%
  • Body Mass Index <35kg/m2
  • NYHA fuctional class
  • ≤1 structured physical activity per week
  • Non-smoker ≥1 year
  • Fasting glycemia <6.0 mmol/L
  • HbA1c <5.7%
• HFpEF participants:
  • Chronic symptomatic HF and LVEF >40% within 12 months before the screening visit (regardless of the imaging modality)
  • One of the following abnormalities:
  • HF requiring hospitallization and IV diuretics within 12 months of study entry
  • NTproBNP >150 pg/ml in sinus rhythm
  • NTproBNP >450 pg/ml in chronic atrial fibrillation